文献速递生殖医学

利用二代测序确定植入前胚胎染色体重排的检测限

Defining the limits of detection for chromosome rearrangements in the preimplantation embryo using next generation sequencing.
PubMed 文献 · Hum Reprod · 2018-01-01

本研究回顾性分析200枚经微阵列比较基因组杂交(array-CGH)诊断为不平衡的胚胎DNA样本,比较二代测序(NGS)与array-CGH的检测一致性。NGS检出285/294(97%)不平衡片段,最终诊断一致率为200/200(100%),44/75(59%)患者携带低于厂商声明20 Mb分辨率的片段,其中35/44(80%)可被NGS检出。

要点

  • NGS可检出小于厂商声明分辨率的染色体不平衡片段。
  • NGS与array-CGH的最终诊断一致率为200/200(100%)。
  • 59%患者携带低于20 Mb的片段,其中80%可被NGS检出。

核心结论

  • NGS能够检测小于厂商声明分辨率的不平衡染色体片段,本研究显示NGS可用于检测≥10 Mb的不平衡染色体重排。

研究设计与样本

  • 回顾性评估2013年11月至2017年4月间两家独立IVF诊所常规PGD中经array-CGH诊断为不平衡的胚胎储存DNA样本,共200枚胚胎来自75名携带染色体重排的患者。

主要发现

  • NGS检出285/294(97%)经array-CGH先前识别的不平衡片段。
  • 最终PGD诊断在200/200(100%)胚胎中一致。
  • 44/75(59%)患者携带低于厂商声明20 Mb分辨率的不平衡染色体片段,其中35/44(80%)患者片段可被NGS检出并保持临床结局一致。

关键数值与推荐

  • 共评估294个不平衡染色体片段。
  • 75名患者中68例为相互易位,3例为臂间倒位,1例为臂内倒位,2例为插入,1例为双重相互易位和倒位。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究子集未包括涉及Y染色体的重排。
  • NGS每条染色体可用bin数少于所用array-CGH平台,因此预测为小但array-CGH仍可检测的染色体重排可能不适合NGS检测,进行理论可行性评估时应考虑此点。
  • 本研究仅研究了一种特定的WGA和NGS工作流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is next generation sequencing (NGS) capable of detecting smaller sub-chromosomal rearrangements in human embryos than the manufacturer's quoted resolution suggests? SUMMARY ANSWER: NGS was able to detect unbalanced chromosome segments smaller than the manufacturer's resolution. WHAT IS KNOWN ALREADY: Array Comparative Genomic Hybridization (array-CGH) has been the gold standard platform used for PGD of chromosome rearrangements. NGS is a viable alternative to array-CGH for PGD of chromosome arrangements given that the manufacturer's guidelines quote a resolution of ≥20 Mb. However, as many patients carry a chromosome rearrangement <20 Mb, the detection limits of NGS warrant further investigation. STUDY DESIGN, SIZE, DURATION: This study involved a retrospective assessment of stored DNA samples from embryos that had previously been diagnosed as unbalanced by array-CGH as part of routine PGD in two separate IVF clinics between November 2013 and April 2017. SurePlex whole genome amplification (WGA) products derived from DNA extracted from an embryo biopsy sample known to carry an unbalanced form of a chromosome rearrangement were subjected to a specific NGS workflow (VeriSeq PGS). The results from the two technologies were compared for each sample. PARTICIPANTS/MATERIALS, SETTING, METHODS: WGA products from 200 embryos known to carry unbalanced rearrangements were sequenced and analysed. These embryos had been created by 75 patients known to carry a chromosome rearrangement (68 reciprocal translocations, 3 pericentric inversions, 1 paracentric inversion, 2 insertions and 1 dual reciprocal and inversion). Each sample was assessed for the size of the segmental gain/loss (Mb), copy number for each segment and chromosome, segregation pattern, the number of bins in the analysis software used and concordance with array-CGH results. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 294 unbalanced chromosome segments were assessed. NGS was capable of detecting 285/294 (97%) unbalanced segments previously identified using array-CGH. The final PGD diagnosis was concordant for 200/200 (100%) embryos. In total, 44/75 (59%) patients contained an unbalanced chromosome segment below the quoted 20 Mb manufacturer's stated resolution. Of these, 35/44 (80%) patients had segments that were able to be detected using NGS, whilst maintaining clinical outcome concordance. LIMITATIONS, REASONS FOR CAUTION: Our study subset did not include any rearrangements involving the Y chromosome. NGS has less available bins per chromosome compared to the array-CGH platform used, thus it remains possible that chromosome rearrangements predicted to be small but still detectable by array-CGH may not be feasible for testing using NGS. This should be considered when undertaking a theoretical feasibility assessment for detecting the chromosome rearrangement in question. Only one specific workflow for WGA and NGS was investigated in this study. WIDER IMPLICATIONS OF THE FINDINGS: This study has shown that NGS is available for the detection of unbalanced chromosome rearrangements ≥10 Mb. STUDY FUNDING/COMPETING INTEREST(S): Part sponsorship of the VeriSeq PGS kits used was provided by Illumina. The remainder of the kits were provided by two commercial IVF clinics. None of the authors has any conflicting interests to declare. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Cuman C, Beyer CE, Brodie D, et al. Defining the limits of detection for chromosome rearrangements in the preimplantation embryo using next generation sequencing. Hum Reprod. 2018. PMID: 30007310. doi:10.1093/humrep/dey227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。